4.4 Article

Cost-effectiveness of home-based care of febrile neutropenia in children with cancer

Journal

PEDIATRIC BLOOD & CANCER
Volume 69, Issue 7, Pages -

Publisher

WILEY
DOI: 10.1002/pbc.29469

Keywords

cost; cost-effectiveness; febrile neutropenia; home care; quality of life

Funding

  1. National Health and Medical Research Council (NHMRC)
  2. Better Care Victoria
  3. Victorian Paediatric Integrated Cancer Service
  4. NHMRC [1116325, 1116876]
  5. Melbourne Research Scholarship
  6. Australian Research Council Centre of Excellence in Population Ageing Research (CEPAR)
  7. National Health and Medical Research Council of Australia [1116876, 1116325] Funding Source: NHMRC

Ask authors/readers for more resources

The study found that home-based treatment of febrile neutropenia in low-risk patients is more cost-effective than in-hospital treatment, with savings arising from cheaper cost of caring for children at home. The home-based program is more effective and less costly compared to in-hospital care. The results are sensitive to the proportion of children eligible for home-based care.
Introduction Home-based treatment of febrile neutropenia (FN) in children with cancer with oral or intravenous antibiotics is safe and effective. There are limited data on the economic impact of this model of care. We evaluated the cost-effectiveness of implementing an FN programme, incorporating home-based intravenous antibiotics for carefully selected patients, in a tertiary paediatric hospital. Methods A decision analytic model was constructed to compare costs and outcomes of the home-based FN programme, with usual in-hospital treatment with intravenous antibiotics. The programme included a clinical decision rule to stratify patients by risk for severe infection and home-based eligibility criteria using disease, chemotherapy and patient-level factors. Health outcomes (quality of life) and probabilities of FN risk classification and home-based eligibility were based on prospectively collected data between 2017 and 2019. Patient-level costs were extracted from hospital administrative records. Cost-effectiveness was expressed as the incremental cost per quality-adjusted life year (QALY). Findings The mean health care cost of home-based FN treatment in low-risk patients was Australian dollars (A$) 7765 per patient compared to A$20,396 for in-hospital treatment (mean difference A$12,632 [95% CI: 12,496-12,767]). Overall, the home-based FN programme was the dominant strategy, being more effective (0.0011 QALY [95% CI: 0.0011-0.0012]) and less costly. Results of the model were most sensitive to proportion of children eligible for home-based care programme. Conclusion Compared to in-hospital FN care, the home-based FN programme is cost-effective, with savings arising from cheaper cost of caring for children at home. These savings could increase as more patients eligible for home-based care are included in the programme.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available